Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204073 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01204073 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 34 participants.
The verdict
NCT01204073, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer effective or does not offer curative or life-prolonging potential. Following completion of the dose escalation study, patients will be enrolled as part of 2 expansion cohorts.
Interventions
- DRUG TAK-441
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204073
The ClinicalTrials.gov registry entry for NCT01204073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-441 is the first listed.
NCT01204073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204073 about?
NCT01204073 is a clinical study titled "A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies". This is the first study in which TAK-441 is administered to humans. The patient population will consist of adults aged 18 or older who have advanced nonhematologic malignancies and for whom standard treatment is no longer effective or does not offer curative or life-prolonging potential. Following c...
What is the current status of trial NCT01204073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01204073?
The interventions under investigation include: TAK-441 (DRUG).
Who is sponsoring clinical trial NCT01204073?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.